The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumour’s TMPRSS2-ERG Fusion Status
Table 1
Aggregated summary of the characteristics of the studied patient cohorts. (A) Demographics of the radical prostatectomy (RP) patient cohort including the 536 patients eligible for statistical data analysis. For patient age, preoperative PSA, percentage of tumour in biopsy, prostate volume, and PSA density the min and max values in the cohort are shown; median and IQR (interquartile range) are shown in parentheses. Pre- and postsurgical pathology is given (Note. extracapsular extension was derived from pathology stage information). The outcome category illustrates the cumulative 5- and 10-year biochemical recurrence (BCR) and clinical recurrence to metastases (CR) postsurgical primary treatment. The treatment category lists the cumulative 5- and 10-year start to SRT (salvage radiation therapy) or SADT (salvage androgen deprivation therapy) after surgery. Mortality is shown as prostate cancer specific survival (PCSS) as well as overall survival (OS) (N/A=not available). (B) Demographics of the diagnostic biopsy (DB) patient cohort. In total diagnostic needle biopsy tissues of 151 were eligible for statistical data analysis. The demographics and clinical data of this cohort are presented equivalent to the RP cohort (N/A=not available).
Parameter
(A) RP cohort (n=536)
(B) DB cohort (n=151)
Demographic & Clinical Range (median; IQR)
Age range (at RP)
41.3-74.5 (62.5; 7.5)
47.4-77.4 (64.9; 8.5)
Preoperative PSA range
0.18-120 (7.1; 6.2)
2.0-49.1 (8.1; 5.7)
Percent tumour in biopsy range
0.2-80.0 (10.6; 20.2)
N/A
Prostate Volume range
9-244 (41.0; 21.0)
13.6-148.0 (38.5; 19.2)
PSA density range
0.01-4.0 (0.17; 0.16)
0.03-1.6 (0.2; 0.17)
CAPRA Risk Category Number of patients (percentage)
Low Risk (CARPA 0-2)
199 (37.1%)
38 (25.2%)
Intermediate Risk (CAPRA 3-5)
273 (50.9%)
82(54.3%)
High Risk (CAPRA>5)
44 (8.2%)
31 (20.5%)
N/A
20 (3.7%)
-
Pre-Surgery Pathology Number of patients (percentage)
Biopsy Gleason 3+3 (GG1)
282 (52.6%)
77 (51.0%)
Biopsy Gleason 3+4 (GG2)
172 (32.1%)
38 (25.2%)
Biopsy Gleason 4+3 (GG3)
46 (8.6%)
20 (13.2%)
Biopsy Gleason >=4+4 (>=GG4)
36 (6.7%)
16 (10.6%)
cT1
348 (64.9%)
97 (64.2%)
cT2
175 (32.6%)
cT3
13 (2.3%)
54 (35.8%)
N/A
1 (0.2%)
-
Post-Surgery Pathology Number of patients (percentage)
Pathology Gleason 3+3 (GG1)
176 (32.8%)
46 (30.5%)
Pathology Gleason 3+4 (GG2)
268 (50.0%)
52 (34.4%)
Pathology Gleason 4+3 (GG3)
69 (12.9%)
31 (20.5%)
Pathology Gleason >=4+4 (>=GG4)
23 (4.3%)
22 (14.6%)
pT2
312 (58.2%)
88 (58.3%)
pT3
224 (41.8%)
63 (41.7%)
pT4
0 (0%)
0 (0%)
Positive Surgical Margins
197 (36.8%)
33 (21.9%)
Extra-Capsular Extension (=T3a)
139 (25.9%)
37/151 (24.5%)
Seminal Vesicle Invasion
87 (16.2%)
N/A
Lymph Node Invasion
17 (3.2%)
10 (6.6%)
Follow-up (months)
Mean
105.1
73.7
Median
120.2
73.6
Outcome– Number events/total patient number (percentage)
BCR within 5 years
169/480 (35.2%)
45/151 (29.8%)
BCR within 10 years
210/402 (52.2%)
-
CR within 5 years
46/472 (9.7%)
4/151 (2.6%)
CR within 10 years
61/337 (18.1%)
-
Salvage Treatment – Number events/total patient number (percentage)
SRT within 5 years
130/475 (27.4%)
12/151 (7.9%)
SRT within 10 years
164/381 (43.0%)
-
SADT within 5 years
75/467 (16.1%)
16/151 (10.6%)
SADT within 10 years
110/350 (31.4%)
-
Survival– Number events/total patient number (percentage)
